



6-14-7

RCE
ZPW

PTO/SB/30 (04-97)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Request for Continued Examination (RCE) Transmittal

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Application Number	10/624,080
Filing Date	July 21, 2003
First Named Inventor	Ganjam V. Kalpana
Art Unit	1645
Examiner Name	Michelle S. Horning
Attorney Docket Number	96700/819

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

a. ☒ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

i. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____

ii. ☒ Other Please enter the Amendment and Reply filed April 13, 2007

b. ☐ Enclosed

i. ☐ Amendment/Reply

iii. ☐ Information Disclosure Statement (IDS)

ii. ☐ Affidavit(s)/ Declaration(s)

iv. ☐ Other _____

2. **Miscellaneous**

a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)

b. ☐ Other _____

3. **Fees**

The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

a. ☒ The Director is hereby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. 01-1785. I have enclosed a duplicate copy of this sheet.

i. ☐ RCE fee required under 37 CFR 1.17(e)

ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17)

iii. ☒ Other any fees required to maintain pendency of application

b. ☒ Check in the amount of \$ 455.00 enclosed

c. ☐ Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Signature		Date	June 13, 2007
Name (Print/Type)	Elie H. Gendloff	Registration No.	44704

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as express mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below. Express Mail No. EV 725833874 US

Signature		Date	June 13, 2007
Name (Print/Type)	Elie H. Gendloff		

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

06/15/2007 HUUNG1 00000022 10624080

01 FC:2801

395.00 OP



Partners
Morton Amster
Jesse Rothstein (1934 - 2003)
Daniel Ebenstein
Philip H. Gottfried
Michael J. Berger
Neil M. Zipkin
Anthony F. Lo Cicero
Kenneth P. George
Abraham Kasdan, Ph.D.
Ira E. Silfin
Chester Rothstein
Craig J. Arnold

Kenneth M. Bernstein
Joseph M. Casino
Michael V. Solomita

Senior Counsel
Charles R. Macedo
John S. Economou
Marion P. Metelski

Associates
Patrick Boland*
Holly Pekowsky
Michael P. Kenney

Max Vern
Karl J. Kolbinger
Brian A. Comack
Richard S. Mandaro
Marc J. Jason
Elie H. Gendloff, Ph.D.
David Mitnick
Charles W. Rath
David A. Boag
Matthieu Hausig
Jung S. Hahn
Reiko Kaji
Alan D. Miller, Ph.D.

Norajean McCaffrey
Benjamin M. Halpern*
Matthew A. Fox
Michael J. Kasdan
Jason M. Rockman
Stuart Shapley
Howard Wizenfeld
Steven B. Gauthier

*Not admitted in New York

June 13, 2007

Elie H. Gendloff, Ph.D., Esq.
Direct 212 336 8108
E-mail egendlof@arelaw.com

Via Express Mail
(EV 725833874 US)

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

"Express Mail" mailing label No.	EV 725833874 US
Date of Deposit:	June 13, 2007
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Name:	Elie H. Gendloff
Signature:	

Re: U.S. Utility Patent Application No. 10/624,080
Title: INHIBITION OF HIV-1 VIRION PRODUCTION BY
A TRANSDOMINANT MUTANT OF INTEGRASE
INTERACTOR 1 (INI1)/Hsnf
Inventor: Ganjam V. Kalpana
Our Files: 96700/819

Dear Sir:

Pursuant to our receipt of a final Office Action dated February 14, 2007 and an Advisory Action dated May 11, 2007 in connection with the above-identified application, enclosed please find the following documents for filing a reply in the name of Ganjam V. Kalpana, entitled INHIBITION OF HIV-1 VIRION PRODUCTION BY A TRANSDOMINANT MUTANT OF INTEGRASE INTERACTOR 1 (INI1)/Hsnf, comprising the following:

1. a "Request for Continued Examination" with a one-month extension of time fee requested therein (2 pages);
2. a "Request for Continued Examination (RCE) Transmittal, Form PTO/SB/30 (1 page);

06/15/2007 HVUONG1 00000022 10624080

02 FC:2251

60.00 0P

372230.1

Commissioner for Patents
Alexandria, VA 22313-1450
Mail Stop RCE
Application Serial No. 10/624,080

-2-

June 13, 2007

3. an Amster Rothstein & Ebenstein LLP check in the amount of \$455 to cover the RCE fee and a one-month extension of time fee, claiming small entity status; and
4. a return receipt postcard.


Small entity status has been previously established and is still proper.

Please acknowledge receipt of the enclosed documents by stamping the enclosed postcard and returning same.

Respectfully submitted,

Amster, Rothstein & Ebenstein LLP
Attorneys for Applicants
90 Park Avenue
New York, NY 10016
212-336-8000

Dated: New York, New York
June 13, 2007

By: 
Elie Gendloff
Registration No. 44,704



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/624,080
Applicant : Ganjam V. Kalpana
Filed : July 21, 2003
Art Unit : 1645
Examiner : Michelle S. Horning
Docket No. : 96700/819
Customer No. : 1912

Confirmation No.: 5994

"Express Mail" mailing label No.	EV 725833874 US
Date of Deposit:	June 13, 2007
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Name:	Elie H. Gendloff
Signature:	

REQUEST FOR CONTINUED EXAMINATION

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Request for Continued Examination (RCE) is in response to the February 14, 2007 final Office Action and May 11, 2007 Advisory Action in the above-identified case. Applicants request a one month extension of time for submitting this RCE. With that extension, this RCE is due June 14, 2007 and is timely filed.

Please enter the Amendment and Reply under 37 C.F.R. 1.116 filed April 13, 2007 for this patent application.

Conclusion


In light of the amendments and remarks made in the Amendment and Reply dated April 13, 2007, applicant requests withdrawal of all rejections and objections and passage of the claims to allowance.

Enclosed herewith is a check for \$455.00, which is the sum of the RCE fee (\$395.00) and the fee for a one month extension of time (\$60.00). If there are any unanticipated fees required to maintain pendency of this patent application, the PTO is hereby authorized to withdraw funds for those fees from Deposit Account 01-1785.

Respectfully submitted

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicant
90 Park Avenue
New York, NY 10016
(212) 336-8000

Dated: New York, New York
June 13, 2007

By: 
Elie H. Gendloff
Registration No.: 44,704